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sites in 16 countries, the initial merger of existing data-
bases has yielded a primary group of 2200 well charac-
terised patients with definite infective endocarditis by
the Duke criteria, allowing the assessment of regional
differences in presentation and outcome. Indeed,
analysis of the dataset has already enabled valuable
insight into emerging epidemiological patterns of the
disease and its clinical presentation.w18-w21 In future, this
platform will provide the basis for sorely needed
adequately sized randomised clinical trials in the man-
agement and treatment of infective endocarditis.w22 w23
The future
Several exciting developments offer the prospect of
improved prevention and treatment of infective endo-
carditis. Vaccines targeted at specific bacterial adhesins
may inhibit valve colonisation, and newer antibacterial
agents with novel effects may attenuate the invasive
properties of virulent organisms such as Staph aureus.1
Finally, modified biomaterials in development may
reduce the risk of infective endocarditis in patients with
artificial heart valves or other intracardiac prosthetic
material. However, despite these advances, the diagno-
sis and management of infective endocarditis remain a
considerable challenge across the range of medical
disciplines.
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Additional educational resources
Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A,
Pavie A, et al. Guidelines on prevention, diagnosis and
treatment of infective endocarditis: executive summary.
Eur Heart J 2004;25:267-76 (www.escardio.org/
knowledge/guidelines/)—A comprehensive document
covering all aspects of the investigation and manage-
ment of infective endocarditis
Baddour LM,Wilson WR, Bayer AS, Fowler VG Jr,
Bolger AF, Levison ME, et al. Infective endocarditis:
diagnosis, antimicrobial therapy, and management of
complications. (circ.ahajournals.org/cgi/content/full/
111/23/e394)—Up to date American Heart Associa-
tion guidelines on the management of endocarditis
British National Formulary (www.bnf.org)—Detailed
explanation of current prophylaxis recommendations
International Collaboration on Endocarditis
(endocarditis.org/ice/index.html)
Information for patients
American Heart Association patient information sheet
(www.americanheart.org/
presenter.jhtml?identifier = 4436)—A good basic guide
written for non-medical personnel
American National Institute for Health information
sheet (www.nlm.nih.gov/medlineplus/ency/article/
000681.htm)—A brief description of infective endocar-
ditis from a patient’s perspective
Patient UK (www.patient.co.uk/showdoc/27000162/
)—A simple description of infective endocarditis from a
UK based site (partially funded by advertisements)
Corrections and clarifications
Pressure relieving support surfaces (PRESSURE) trial:
cost effectiveness analysis
This research article by Cynthia Iglesias and
colleagues (BMJ 2006;332:1416-8, 17 Jun) should
have included the trial registration identifier
Current Controlled Trials ISRCTN78646179.
Correction for Nixon et al
In the correction (BMJ 2006;333:30, 1 Jul) to the
article “Randomised, controlled trial of alternating
pressure mattresses compared with alternating
pressure overlays for the prevention of pressure
ulcers: PRESSURE (pressure relieving support
surfaces) trial” (BMJ 2006;332 1413-5, 17 Jun), we
incorrectly referred to haemoglobin levels rather
than odds ratios. We should have said: “In table 4 of
the full version on bmj.com (table 2 of the abridged
version), the odds ratio for haemoglobin levels on
admission or preoperatively should be 0.89 (0.82 to
0.97), and the corresponding P value should be 0.01.”
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